PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Hassannia, B.* ; Wiernicki, B.* ; Ingold, I. ; Qu, F.* ; Van Herck, S.* ; Tyurina, Y.Y.* ; Bayir, H.* ; Abhari, B.A.* ; Angeli, J.P.F.* ; Choi, S.M.* ; Meul, E.* ; Heyninck, K.* ; Declerck, K.* ; Chirumamilla, C.S.* ; Lahtela-Kakkonen, M.* ; Van Camp, G.* ; Krysko, D.V.* ; Ekert, P.G.* ; Fulda, S.* ; De Geest, B.G.* ; Conrad, M. ; Kagan, V.E.* ; Berghe, W.V.* ; Vandenabeele, P.* ; Berghe, T.V.*

Nano-targeted induction of dual ferroptotic mechanisms eradicates high-risk neuroblastoma.

J. Clin. Invest. 128, 3341-3355 (2018)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
High-risk neuroblastoma is a devastating malignancy with very limited therapeutic options. Here, we identify withaferin A (WA) as a natural ferroptosis-inducing agent in neuroblastoma, which acts through a novel double-edged mechanism. WA dose-dependently either activates the nuclear factor-like 2 pathway through targeting of Kelch-like ECH-associated protein 1 (noncanonical ferroptosis induction) or inactivates glutathione peroxidase 4 (canonical ferroptosis induction). Noncanonical ferroptosis induction is characterized by an increase in intracellular labile Fe(II) upon excessive activation of heme oxygenase-1, which is sufficient to induce ferroptosis. This double-edged mechanism might explain the superior efficacy of WA as compared with etoposide or cisplatin in killing a heterogeneous panel of high-risk neuroblastoma cells, and in suppressing the growth and relapse rate of neuroblastoma xenografts. Nano-targeting of WA allows systemic application and suppressed tumor growth due to an enhanced accumulation at the tumor site. Collectively, our data propose a novel therapeutic strategy to efficiently kill cancer cells by ferroptosis.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
13.251
2.585
160
244
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Drug Therapy ; Nanotechnology ; Neurological Disorders ; Neuroscience ; Oncology; Cell-death; Cancer-cells; Oxidative Stress; Withania-somnifera; Tumor-growth; Iron; Therapy; Pathway; Expression; Gpx4
Sprache englisch
Veröffentlichungsjahr 2018
HGF-Berichtsjahr 2018
ISSN (print) / ISBN 0021-9738
e-ISSN 1558-8238
Zeitschrift Journal of Clinical Investigation
Quellenangaben Band: 128, Heft: 8, Seiten: 3341-3355 Artikelnummer: , Supplement: ,
Verlag American Society of Clinical Investigation
Verlagsort 2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Developmental Genetics (IDG)
POF Topic(s) 30204 - Cell Programming and Repair
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-500500-001
G-508100-030
DOI 10.1172/JCI99032
WOS ID WOS:000440461500020
Scopus ID 85051261318
PubMed ID 29939160
Erfassungsdatum 2018-07-02
[➜Korrektur melden]